SOLV Stock Chart & Stats
$1382.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1382.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,080.01 - $1,572.99
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$252.62B
Enterprise Value$18.25K
Total Cash (Recent Filing)$403.00M
Total Debt (Recent Filing)$5.29B
Price to Earnings (P/E)10.6
Beta-0.57
Next Earnings
Nov 05, 2026EPS Estimate
22.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.22
Shares Outstanding170,223,720
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.73
Price to Sales (P/S)1.66
P/FCF Ratio-1.38K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,664.61Price Target Upside20.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)120.93
Revenue Forecast (FY)$139.18B
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Raised GuidanceHealthy profitability and materially higher full-year guidance indicate improving earnings power and management confidence. If operating execution holds after excluding one-time benefits, stronger margins and earnings can support reinvestment, resilience, and sustained value creation over the coming quarters.
Growth In Dental And MedSurgGrowth across core Dental and MedSurg franchises supports Solventum’s position in recurring healthcare-product markets. Dental launches and strong procedure-linked demand can broaden the product base, improve customer engagement, and provide durable organic growth beyond individual quarterly timing effects.
Transformation And Product InnovationProgress on separation, systems migration, and transition-service exits should simplify operations and reduce execution burdens over time. A multi-year product pipeline also creates opportunities to move customers toward higher-value solutions, supporting competitiveness and future growth across the focused MedTech portfolio.
Bears Say
Weak Current Cash GenerationThe sharp deterioration in operating and free cash flow weakens the quality of current earnings and limits internally funded investment. Continued cash burn would constrain debt reduction, acquisitions, and shareholder returns, while making execution of the transformation more dependent on improved working capital and later-period cash generation.
Meaningful LeverageMeaningful leverage reduces financial flexibility and leaves less room to absorb operating setbacks or fund strategic initiatives internally. Debt obligations can also compete with investment in innovation and separation execution, making balance-sheet improvement an important condition for more durable financial resilience.
Uneven And Less Predictable Revenue GrowthInconsistent revenue growth makes it harder to assess the underlying pace of customer adoption and market expansion. A sharp recent acceleration following weaker periods may not represent a stable trend, increasing the risk that future planning, margin leverage, and earnings expectations rely on growth that proves difficult to repeat.
Solventum Corporation News
SOLV FAQ
What was Solventum Corporation’s price range in the past 12 months?
Solventum Corporation lowest stock price was $1080.01 and its highest was $1572.99 in the past 12 months.
What is Solventum Corporation’s market cap?
Solventum Corporation’s market cap is $252.62B.
When is Solventum Corporation’s upcoming earnings report date?
Solventum Corporation’s upcoming earnings report date is Nov 05, 2026 which is in 53 days.
How were Solventum Corporation’s earnings last quarter?
Solventum Corporation released its earnings results on Aug 05, 2026. The company reported $43.373 earnings per share for the quarter, beating the consensus estimate of $32.402 by $10.971.
Is Solventum Corporation overvalued?
According to Wall Street analysts Solventum Corporation’s price is currently Undervalued.
Does Solventum Corporation pay dividends?
Solventum Corporation does not currently pay dividends.
What is Solventum Corporation’s EPS estimate?
Solventum Corporation’s EPS estimate is 22.88.
How many shares outstanding does Solventum Corporation have?
Solventum Corporation has 170,223,720 shares outstanding.
What happened to Solventum Corporation’s price movement after its last earnings report?
Solventum Corporation reported an EPS of $43.373 in its last earnings report, beating expectations of $32.402. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solventum Corporation?
Currently, no hedge funds are holding shares in MX:SOLV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solventum Corporation Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,664.61 (20.45% Upside)
$1,664.61 (20.45% Upside)
Blogger Sentiment
Neutral
MX:SOLV Sentiment 57%
Sector Average 62%
Sector Average 62%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
18.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-5.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
SOLV Company Deck
SOLV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive tone: the company beat expectations on top and bottom lines, raised full-year guidance (organic growth, operating margin, EPS, and free cash flow), accelerated share repurchases, showed strong segment performance (especially Dental and MedSurg) and highlighted successful M&A (Acera) and progress on separation/ERP migration and product pipeline. Notable near-term headwinds include ERP advanced-order timing that will reverse in Q3 (creating quarter-to-quarter volatility), tariff and inflation pressures (partly offset by a one-time $100M tariff refund), material litigation charges, and separation-related cash demands. Overall, management presented confidence in transformation execution and a pathway to improved cash flow and margin expansion despite measurable one-time and timing-related challenges.View all MX:SOLV earnings summariesSOLV Stock 12 Month Forecast
Average Price Target
$1,664.61
▲(20.45% Upside)
Technical Analysis
Baxter International
―
Becton Dickinson
―
Teleflex
―
West Pharmaceutical Services
―
Avantor
―